Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-21-036486
Filing Date
2021-03-16
Accepted
2021-03-15 19:51:37
Documents
1
Group Members
RICHARD AMMER, M.D., PH.D.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tm218763d1_sc13da.htm SC 13D/A 69699
  Complete submission text file 0001104659-21-036486.txt   71298
Mailing Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103
Business Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103 (267) 207-3606
Vallon Pharmaceuticals, Inc. (Subject) CIK: 0001824293 (see all company filings)

EIN.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92206 | Film No.: 21743168
SIC: 2834 Pharmaceutical Preparations

Mailing Address SANKT-JACOBS-STRASSE 90 CH-9002 BASEL V8 4052
Business Address SANKT-JACOBS-STRASSE 90 CH-9002 BASEL V8 4052 61 3137965
SALMON Pharma GmbH (Filed by) CIK: 0001843677 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13D/A